Indigo BioAutomation built a quiet business around an expensive laboratory habit: highly trained scientists checking good data one result at a time. Its bet is that software should clear the routine cases and make humans spend their attention on the exceptions.
The laboratory software veteran survived an IPO, a $123 million sale, a 12-year corporate hibernation and a private-equity rebirth. Its next experiment is harder: turning a sprawling enterprise stack into one usable thread from scientific idea to released product.